Cocrystal Pharma Inc
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
stocks
The ASX data center stock flying under the radar
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,021.80 | 28.10 | -0.31% |
| CAC 40 | 8,382.43 | 15.58 | 0.19% |
| DAX 40 | 24,999.53 | 147.50 | -0.59% |
| Dow JONES (US) | 52,658.64 | 150.37 | 0.29% |
| FTSE 100 | 10,515.92 | 13.47 | -0.13% |
| HKSE | 25,157.56 | 476.46 | 1.93% |
| NASDAQ | 26,269.23 | 162.22 | 0.62% |
| Nikkei 225 | 67,044.71 | 1,706.80 | -2.48% |
| NZX 50 Index | 13,608.61 | 26.46 | -0.19% |
| S&P 500 | 7,572.40 | 28.81 | 0.38% |
| S&P/ASX 200 | 8,825.90 | 30.30 | -0.34% |
| SSE Composite Index | 3,923.20 | 32.38 | -0.82% |